VALERIO THERAPEUTICS
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
49 Boulevard Du Général Martial Valin, P...Phone Number
+33 170383399Website
www.valeriotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About VALERIO THERAPEUTICS
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops innovative drugs targeting tumor DNA functions through unique mechanisms in the field of DNA Damage Response. The company focuses on creating first-in-class treatments for oncology and inflammatory diseases by designing precision therapeutics that progress from preclinical research to clinical proof-of-concept studies. Valerio Therapeutics' portfolio is built on their proprietary platON decoy oligonucleotide platform, which generates compounds with novel DDR decoy mechanisms. Their lead product, AsiDNA, interferes with tumor DNA break repair and is currently in clinical development in combination with various therapies. The company is also developing new-generation PARP agonists designed to activate immune response without inducing resistance, with their compound VIO-01 in preclinical optimization phase.Explore more
VALERIO THERAPEUTICS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VALERIO THERAPEUTICS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if VALERIO THERAPEUTICS had a recent Job posting/layoffs
VALERIO THERAPEUTICS, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at VALERIO THERAPEUTICS
Check if VALERIO THERAPEUTICS has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on VALERIO THERAPEUTICS recently announced quarterly report
Check out if VALERIO THERAPEUTICS is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once VALERIO THERAPEUTICS has new funding data
Product Launch: Get notified when VALERIO THERAPEUTICS launches new products
Recommended Actions
Find VP level buyers at VALERIO THERAPEUTICS
Find 3 more new buyers
Company Profile Activity
Activity Insights
VALERIO THERAPEUTICS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VALERIO THERAPEUTICS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VALERIO THERAPEUTICS.
VALERIO THERAPEUTICS Tech Stack
A closer look at the technologies used by VALERIO THERAPEUTICS
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Project
Product Management, Shut Down, Medical Research, Clinical Operations, Corporate Strategy
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
VALERIO THERAPEUTICS News & Media
Valerio Therapeutics Announces Strategic Refocus - Business Wire
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials andMeeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
PARIS--(BUSINESS WIRE)--Regulatory News: At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), (“Valerio Therapeutics” or the “Company”) decided to appoint Mr Julien Miara as CEO and Chairman of the Board of Valerio Therapeutics, succeeding Ms Shefali Argawal, effective immediately. Future evolutions related to the Company’s governance will be announced at a later date.Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based ...
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the development oValerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company
PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics, today announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie, one of France's leading cancer centers. Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio con
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VALERIO THERAPEUTICS
Sign Up For FreeTo access detailed company insights
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops innovative drugs targeting tumor DNA functions through unique mechanisms in the field of DNA Damage Response. The company focuses on creating first-in-class treatments for oncology and inflammatory diseases by designing precision therapeutics tha... Read More
